Literature DB >> 7623442

Tyrosinaemia type 1 and glutathione synthetase deficiency: two disorders with reduced hepatic thiol group concentrations and a liver 4-fumarylacetoacetate hydrolase deficiency.

A J Lloyd1, R G Gray, A Green.   

Abstract

Thiol groups are important components of proteins and their oxidation can lead to a substantial loss of protein function. Patients with two apparently unrelated inborn errors of metabolism, tyrosinaemia type 1 and glutathione synthetase deficiency, have been reported to show reduced cell glutathione concentrations. We have found that not only glutathione but also protein thiol concentrations are reduced in the liver in tyrosinaemia type 1 patients. We also report a case of glutathione synthetase deficiency with a substantial deficiency of liver 4-fumarylacetoacetate hydrolase and provide evidence that glutathione, or some small-molecular-weight thiol, is essential for maintaining stability of this enzyme in vitro. Our results suggest that the availability of thiol groups may modify the phenotype of tyrosinaemia type 1 and that liver 4-fumarylacetoacetate hydrolase deficiency may be a secondary complicating factor in some forms of glutathione synthetase deficiency.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7623442     DOI: 10.1007/bf00711372

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  20 in total

1.  5-Oxoprolinuria (glutathione synthetase deficiency): a case with neonatal presentation and rapid fatal outcome.

Authors:  P Divry; F Roulaud-Parrot; C Dorche; M T Zabot; B Contraire; L Hagenfeldt; A Larsson
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

Review 2.  Strategies of antioxidant defense.

Authors:  H Sies
Journal:  Eur J Biochem       Date:  1993-07-15

3.  Deficiency of fumarylacetoacetase without hereditary tyrosinemia.

Authors:  E A Kvittingen; A L Børresen; O Stokke; C B van der Hagen; S O Lie
Journal:  Clin Genet       Date:  1985-06       Impact factor: 4.438

4.  Erythrocyte glutathione synthetase deficiency leads not only to glutathione but also to glutathione-S-transferase deficiency.

Authors:  E Beutler; T Gelbart; C Pegelow
Journal:  J Clin Invest       Date:  1986-01       Impact factor: 14.808

5.  Assay of fumarylacetoacetate fumarylhydrolase in human liver-deficient activity in a case of hereditary tyrosinemia.

Authors:  E A Kvittingen; E Jellum; O Stokke
Journal:  Clin Chim Acta       Date:  1981-09       Impact factor: 3.786

6.  Measurement of protein using bicinchoninic acid.

Authors:  P K Smith; R I Krohn; G T Hermanson; A K Mallia; F H Gartner; M D Provenzano; E K Fujimoto; N M Goeke; B J Olson; D C Klenk
Journal:  Anal Biochem       Date:  1985-10       Impact factor: 3.365

7.  Cloning and expression analysis of a cDNA encoding fumarylacetoacetate hydrolase: post-transcriptional modulation in rat liver and kidney.

Authors:  Y Labelle; D Phaneuf; R M Tanguay
Journal:  Gene       Date:  1991-08-15       Impact factor: 3.688

8.  On the enzymic defects in hereditary tyrosinemia.

Authors:  B Lindblad; S Lindstedt; G Steen
Journal:  Proc Natl Acad Sci U S A       Date:  1977-10       Impact factor: 11.205

9.  Different molecular basis for fumarylacetoacetate hydrolase deficiency in the two clinical forms of hereditary tyrosinemia (type I).

Authors:  R M Tanguay; J P Valet; A Lescault; J L Duband; C Laberge; F Lettre; M Plante
Journal:  Am J Hum Genet       Date:  1990-08       Impact factor: 11.025

10.  Murine fumarylacetoacetate hydrolase (Fah) gene is disrupted by a neonatally lethal albino deletion that defines the hepatocyte-specific developmental regulation 1 (hsdr-1) locus.

Authors:  M L Klebig; L B Russell; E M Rinchik
Journal:  Proc Natl Acad Sci U S A       Date:  1992-02-15       Impact factor: 11.205

View more
  3 in total

1.  Fumarate Mediates a Chronic Proliferative Signal in Fumarate Hydratase-Inactivated Cancer Cells by Increasing Transcription and Translation of Ferritin Genes.

Authors:  Michael John Kerins; Ajay Amar Vashisht; Benjamin Xi-Tong Liang; Spencer Jordan Duckworth; Brandon John Praslicka; James Akira Wohlschlegel; Aikseng Ooi
Journal:  Mol Cell Biol       Date:  2017-05-16       Impact factor: 4.272

2.  Abnormal glutathione conjugation in patients with tyrosinaemia type I.

Authors:  T M Mulders; D J Bergman; B T Poll-The; G P Smit; D D Breimer; G J Mulder; M Duran; J A Smeitink
Journal:  J Inherit Metab Dis       Date:  1997-08       Impact factor: 4.982

3.  Evaluation of dynamic thiol/disulfide homeostasis in hereditary tyrosinemia type 1 patients.

Authors:  Ayse Cigdem Aktuglu Zeybek; Ertugrul Kiykim; Salim Neselioglu; Halise Zeynep Iscan; Tanyel Zubarioglu; Mehmet Serif Cansever; Ozcan Erel
Journal:  Pediatr Res       Date:  2021-10-09       Impact factor: 3.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.